Core Points - The Company has received shareholder approval to extend the deadline for completing an initial business combination from July 11, 2024, to April 11, 2025, with the option to extend monthly for up to nine additional months [7] - A deposit of $15,063.74 has been made into the Trust Account to fund the one-month extension, which is the lesser of $20,000 or $0.02 per public share not redeemed prior to the extension [2] - The deposit was funded through a convertible promissory note of up to $180,000 issued to the Sponsor, which is interest-free and repayable upon the consummation of the business combination or liquidation [2] Company Information - Denali Capital Acquisition Corp. is a blank check company incorporated in the Cayman Islands, aimed at effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination [8] - The Company filed the Definitive Proxy Statement with the SEC on June 28, 2024, in connection with the solicitation of proxies for the Shareholder Meeting [5]

Core Insights - Semnur Pharmaceuticals, Inc. is set to undergo a proposed business combination with Denali Capital Acquisition Corp., with a pre-transaction equity value of up to $2.0 billion and expected gross proceeds of up to $40 million [13][26] - The combined company will focus on the development and commercialization of SP-102 (SEMDEXA™), a non-opioid injectable corticosteroid gel for treating lumbar radicular pain or sciatica, which has completed a Phase 3 study and received FDA Fast Track status [5][39] - The market for chronic pain management is significant, with over 30 million people in the U.S. suffering from low back and radicular pain, highlighting the need for effective non-opioid therapies [14][40] Company Overview - Semnur Pharmaceuticals is a clinical-late stage specialty pharmaceutical company focused on non-opioid pain therapies, with its lead program SP-102 being a novel gel formulation for chronic radicular pain [39][44] - Scilex Holding Company, the parent company of Semnur, is dedicated to acquiring and developing non-opioid pain management products, targeting high unmet needs in the pain management market [43] Product Development - SP-102 (SEMDEXA™) is a viscous gel formulation containing 10 mg of dexamethasone sodium phosphate, designed for epidural injections to treat sciatica, showing significant clinical benefits in trials [5][39] - The product has demonstrated a decrease in pain intensity for over a month in patients and has shown statistically significant improvements in disability index scores [39] Market Potential - The peak sales potential for SP-102 is projected to reach up to $3.6 billion annually five years post-launch, indicating a strong market opportunity for the product [27] - The overall estimated number of epidural steroid injection procedures in the U.S. is approximately 12.1 million, with lumbar radiculopathy/sciatica procedures comprising about 88% of these, underscoring the demand for effective treatments [40]

Company Announcement - Denali Capital Acquisition Corp and Longevity Biomedical Inc have mutually agreed to terminate their previously announced business combination agreement [3] - The company and its sponsor intend to seek alternative ways to consummate an initial business combination [3] Company Overview - Denali Capital Acquisition Corp is a blank check company incorporated as a Cayman Islands exempted company [4] - The company's purpose is to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities [4]

Group 1 - Denali Capital Acquisition Corp. has mutually agreed to terminate its business combination agreement with Longevity Biomedical, Inc. [2] - The company and its sponsor are exploring alternative methods to complete an initial business combination [2] - Denali Capital Acquisition Corp. is a blank check company incorporated in the Cayman Islands, aimed at merging or acquiring businesses [1]

Group 1 - Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. have mutually agreed to terminate their business combination agreement [1] - The company and its sponsor are looking for alternative ways to complete an initial business combination [1][2] - Denali Capital Acquisition Corp. is a blank check company incorporated in the Cayman Islands, aimed at effecting mergers, share exchanges, asset acquisitions, and similar business combinations [2]

Company Overview - Denali Capital Acquisition Corp. is a blank check company incorporated in the Cayman Islands, aimed at executing a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities [3]. Recent Developments - On June 11, 2024, Denali Capital Acquisition Corp. announced the deposit of $50,000 into its trust account to extend the deadline for completing its business combination by one month, from June 11, 2024, to July 11, 2024 [2].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) For the quarterly period ended March 31, 2024 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period______ from to______ Commission File No. 001-41351 DENALI CAPITAL ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands 98-1659463 (S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____. Commission File Number: 001-41351 Securities registered pursuant to Section 12(b) of the Act: | | | Name of each exchange on which | | --- | --- | -- ...

NEW YORK, March 11, 2024 /PRNewswire/ -- Denali Capital Acquisition Corp. (NASDAQ: DECA) (the "Company") announced today that an aggregate of $50,000 has been deposited into the Company's trust account to further extend the period of time the Company has to consummate its business combination by an additional month from March 11, 2024 to April 11, 2024 in accordance with the amended terms of the Company's amended and restated memorandum and articles of association. About the Company Denali Capital Acquisiti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period______ from to______ Commission File No. 001-41351 DENALI CAPITAL ACQUISITION CORP. (Exact name of registrant as specified in its charter) Cayman Islands 98-165946 ...